BOSTON and WILMINGTON, Del.–(BUSINESS WIRE)–MorphoSys US Inc., a wholly owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final follow-up data. five-year ups from the Phase 2 L-MIND study demonstrating that Monjuvi® (tafasitamab-cxix) combined with lenalidomide followed by Monjuvi monotherapy provided sustained and durable responses in adult patients with diffuse large B-cell lymphoma (DLBCL) relapsed or refractory.
The original text of this announcement, written in the source language, is the official version which is authentic. Translations are offered solely for the convenience of the reader and must refer to the text in the original language, which is the only legally valid one.
Contacts
For more information:
MorphoSys
Media:Thomas Biegi
Vice president
Tel: +49 (0)89 / 89927 26079
[email protected]
Kaitlyn Nealy
Senior Director
Tel: +1 857-283-3945
[email protected]
Investors: Dott.ssa Julia Neugebauer
Head of Investor Relations
Tel: +49 (0)89 / 899 27 179
[email protected]
IncyteMedia: Jennifer Antonacci
Executive Director, Public Affairs
Tel: +1 302 498 7036
[email protected]
Investor: Christine Chiou
Senior Director, Investor Relations
Tel: +1 302 498 6171
[email protected]